- Ticker
- ADMP
- Price
- 0.49
- Stock movement down
- -0.01 (-2.97%)
- Company name
- Adamis Pharma
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers-Specialty & Generic
- Market cap
- 1.17M
- Ent value
- 11.67M
- Price/Sales
- 0.20
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -27.96%
- 1 year return
- -95.33%
- 3 year return
- -78.70%
- 5 year return
- -69.87%
- 10 year return
- -49.20%
Last updated: 2024-04-08
DIVIDENDS
ADMP does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.20 |
| Price to Book | - |
| EV to Sales | 1.96 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 2.38M |
| EPS (TTM) | -21.00 |
| FCF per share (TTM) | -20.24 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.95M |
| Gross profit (TTM) | -2.39M |
| Operating income (TTM) | -41.15M |
| Net income (TTM) | -44.95M |
| EPS (TTM) | -21.00 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -40.16% |
| Operating margin (TTM) | -691.51% |
| Profit margin (TTM) | -755.43% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.08M |
| Net receivables | 1.05M |
| Total current assets | 9.27M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 10.93M |
| Accounts payable | 7.94M |
| Short/Current long term debt | 342.56K |
| Total current liabilities | 11.40M |
| Total liabilities | 11.58M |
| Shareholder's equity | -650.76K |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -42.78M |
| Capital expenditures (TTM) | 588.92K |
| Free cash flow (TTM) | -43.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -411.23% |
| Return on Invested Capital | 14584.95% |
| Cash Return on Invested Capital | 14063.10% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.50 |
| Daily high | 0.52 |
| Daily low | 0.49 |
| Daily Volume | 90K |
| All-time high | 128494.41 |
| 1y analyst estimate | 29.40 |
| Beta | 1.26 |
| EPS (TTM) | -21.00 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 13 May 2024 |
Downside potential
Loading...
Downside potential data
| ADMP | S&P500 | |
| Current price drop from All-time high | -100.00% | -9.18% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 9 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -80.80% | -11.35% |
| Avg time to new high | 259 days | 13 days |
| Max time to new high | 5910 days | 1805 days |
COMPANY DETAILS
Marketcap
1.17M
Marketcap category
Small-cap
Description
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injectable pre-filled single dose syringe products for use in the emergency treatment of acute allergic reactions comprising anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was founded in 2006 and is headquartered in San Diego, California.
Employees
11
Investor relations
-
SEC filings
CEO
Dennis J. Carlo
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner